• Molecular NameTriazolam
  • SynonymDEA No; 2887; Triazolamum [INN-Latin]
  • Weight343.217
  • Drugbank_IDDB00897
  • ACS_NO28911-01-5
  • Show 3D model
  • LogP (experiment)2.42
  • LogP (predicted, AB/LogP v2.0)2.88
  • pkaN/A
  • LogD (pH=7, predicted)2.88
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.96
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.1
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds1
  • TPSA39.99
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA benzodiazepine derivative drug. It possesses pharmacological properties similar to that of other benzodiazepines, but it is generally only used as a sedative to treat insomnia.
  • Absorption_value85.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability44.0
  • Protein binding88.1
  • Volume of distribution (VD)1 to 2 L/kg, also quoted as 65 L (mean).
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life1.5~3 h (triazolam); 4 h (1-hydroxymethyltriazolam)
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include drowsiness, slurred speech, motor inco-ordination, coma, and respiratory depression.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A